Yuan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuan Zhang has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Bin Yue
Department of Bone Oncology, The Affiliated Hospital of Qingdao University, China
17 shared publications - Bingxin Zheng
Department of orthopedic oncology, The Affiliated Hospital of Qingdao University, Qingdao, China
17 shared publications - Haitian Hu
Center for Cancer Biology, School of Basic Medical Sciences, Tsinghua University, Beijing, China
17 shared publications - Hanqiu Zheng
State Key Laboratory of Molecular Oncology and Center for Cancer Biology, School of Basic Medical Sciences, Tsinghua University, Beijing, China
17 shared publications - Huijuan Fan
State Key Laboratory of Molecular Oncology and Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China
17 shared publications - Ke Yao
School of Pharmaceutical Sciences, Tsinghua University, Beijing, China
17 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 642, 218289
High-throughput drug screening for targeting polyploid cancer cells with an interactive web portal
- 2 February 2026
- Published by Elsevier in Cancer Letters
- Vol. 642, 218289
Open AccessHigh-throughput drug screening for targeting polyploid cancer cells with an interactive web portal
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Metabolomics of macrophages vs osteaoclasts
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Metabolomics of macrophages vs osteaoclasts
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S4 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S4 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S4 is related to Figure 5 (Olaparib + Zoledronate group).
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Metabolomics of macrophages vs osteaoclasts
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Metabolomics of macrophages vs osteaoclasts
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S3 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S3 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S1 is related to Figure 5 (Vehicle-only group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S1 is related to Figure 5 (Vehicle-only group).
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S2 is related to Figure 5 (Olaparib-only group).
- Open Access
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S3 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).
- 1 February 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S3 from Osteoclast Cancer Cell Metabolic Cross-talk Confers PARP Inhibitor Resistance in Bone Metastatic Breast Cancer
Supplementary Video S3 is related to Figure 5 (Zoledronate-only group).